Credit Suisse Believes Alnylam Pharma (NASDAQ: ALNY) Won’t Stop Here

By Austin Angelo

In a report issued on August 10, Alethia Young from Credit Suisse maintained a Buy rating on Alnylam Pharma (NASDAQ: ALNY), with a price target of $96. The company’s shares closed yesterday at $78.22, close to its 52-week high of $86.92.

According to, Young is a 3-star analyst with an average return of 2.7% and a 52.1% success rate. Young covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Ionis Pharmaceuticals Inc, and Alexion Pharmaceuticals.

Currently, the analyst consensus on Alnylam Pharma is Moderate Buy and the average price target is $92.64, representing a 18.4% upside.

In a report issued on July 27, Bernstein also initiated coverage with a Buy rating on the stock with a $99 price target.

Based on Alnylam Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $15.93 million and GAAP net loss of $118 million. In comparison, last year the company earned revenue of $8.71 million and had a GAAP net loss of $90.13 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALNY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.